
Gimv invests €30m in Spineart
Belgian investor Gimv has invested €30m of growth capital in Swiss medical device company Spineart.
The proceeds will be used for product development, to improve the company's sales and for further expansion in Europe and the US.
The deal marks Gimv's fourth investment in the healthcare space this year. In May, the firm backed the $25m series-D for Dutch biotech business Endostim, alongside Endeavour Vision, Wellington Partners and others.
Company
Founded in 2005 and based in Geneva, Spineart is a medical device company. It focuses on spinal surgery by developing technologies in the fields of motion preservation, fusion, biologics, minimally invasive surgery and fractures treatment. It sells implants with instrument sets. The business employs 100 people and has a turnover of €34m.
People
Gimv – Peter Byloos (partner).
Spineart – Jérome Levieux, Stéphane Mugnier-Jacob (co-CEOs).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater